Magazine Article | January 1, 2016

Nano Aids Pharma In The Business Of Delivering Chemo

Source: Life Science Leader

By Louis Garguilo, Chief Editor, Outsourced Pharma
Follow Me On Twitter @Louis_Garguilo

Michael Benchimol doesn’t want to compete with “conventional medicine.” At least not yet. The founder and chief technology officer of Sonrgy, Inc., a nanotechnology drug-delivery start-up based in San Diego, says, “Some in the pharma industry still view nanomedicine as competitive to their efforts. Instead, we are complementary to products they’re developing. Nano can build on existing therapeutics in completely orthogonal ways to open new doors for patients.”

Orthogonal ways? “I’m referring to how nanomedicine can change the distribution of a drug without altering the chemistry of the compound,” he says. “This type of independent control over the kinetics of a drug is orthogonal. Basically, we leverage the great work pharma scientists have put into developing their compounds and build on that success for patients.”